Sponsored Links
FTC approves Valeant buy with asset sales
WASHINGTON |
WASHINGTON (Reuters) - Antitrust regulators approved Valeant Pharmaceutical's (VRX.TO) acquisition of the dermatology units of Sanofi and Johnson & Johnson, on the condition that it sell the rights to three prescription drugs, the Federal Trade Commission said on Monday.
Valeant is in the process of acquiring Ortho Dermatologics, Inc. from Johnson & Johnson (JNJ.N), and Dermik Laboratories, Inc. from Sanofi Aventis SASY.PA..
(Reporting by Diane Bartz; Editing by Derek Caney)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints


Follow Reuters